• NICE nod for BMS’ Opdivo in advanced oesophageal cancer pharmatimes
    May 17, 2021
    The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) Opdivo for the treatment of unresectable advanced oesophageal squamous cell cancer (OSCC).
PharmaSources Customer Service